Triptan-Related Adverse Events in a Multicenter, Open-Label, Long-Term, Safety Study of DFN-02 (Tosymraâ.,¢; An Intranasal Spray of Sumatriptan 10 mg Plus Permeation Enhancer DDM) for the Acute Treatment of Migraine

Authors
Category Primary study
JournalPostgraduate Medicine
Year 2019
This article has no abstract
Epistemonikos ID: 1afb6f8f5a43ab8abba77eb2de1ba6c4a3b3c413
First added on: Apr 02, 2025